Floatz Rating
C39/100
Confidence
Indicative
Sponsor
SmartNuclide Biopharma
Modality
radiopharmaceutical
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07595237CT.gov A IIT Study of 177Lu-DOTA-SNA040 | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bile Duct Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 177lu-dota-sna040 (this asset) | SmartNuclide Biopharma | Early P1 | C · 39 |
| Capecitabine | University of Washington | P1 | CC |
| Elimusertib | National Cancer Institute (NCI) | P1 | CC |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P1 | CC |
| Ropidoxuridine | National Cancer Institute (NCI) | P1 | CC |
| cgx1321 | Curegenix Inc. | P1 | CC |
| [68Ga]Ga-DOTA-H2D3 | RenJi Hospital | N/A | D |
| [18f]f-resca-g5 | RenJi Hospital | N/A | D |
| [68Ga]Ga-NOTA-WWH347 | RenJi Hospital | N/A | D |
+8 more in the Bile Duct Carcinoma cohort
Other indications for 177lu-dota-sna040
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | Early P1 | C · 39 |
| Gastroesophageal Junction Adenocarcinoma | — | Early P1 | C · 39 |
| Pancreatic Neoplasm | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 177lu-dota-sna040 in Bile Duct Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/177lu-dota-sna040-bile-duct-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →